Drug Type Small molecule drug |
Synonyms Brimonidine/bimatoprost |
Action agonists |
Mechanism ADRA2 agonists(Adrenergic receptors alpha-2 agonists), Prostanoid receptor agonists |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H16BrN5O6 |
InChIKeyQZHBYNSSDLTCRG-LREBCSMRSA-N |
CAS Registry70359-46-5 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glaucoma, Open-Angle | Phase 2 | United States | 01 Jun 2013 |
Phase 2 | 112 | (Fixed-Combination Bimatoprost/Brimonidine) | zkatcxiodf(irawlailxx) = hzcrxgmjkg uyscryssxj (tqzxxmngrv, fjmvriazcr - hyjrhurkov) View more | - | 26 Jan 2015 | ||
Vehicle Ophthalmic Solution+Bimatoprost Ophthalmic Solution 0.01% (Bimatoprost Ophthalmic Solution 0.01% and Vehicle) | zkatcxiodf(irawlailxx) = zhngizbkzn uyscryssxj (tqzxxmngrv, iaxdexthrc - zmkecaqcex) View more |





